TABLE 4.
CSF marker | AD | MCI | CU | AD, MCI, CU Aβ+ | AD, MCI, CU Aβ‐ | AD, MCI, CU | MCI, CU | CUf | FTD‐related syndromes | DLB | VaD | EAD | PSP | CBS | Other |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NfL |
|
||||||||||||||
Ng | |||||||||||||||
α‐Syn | |||||||||||||||
β‐Syn | |||||||||||||||
Contactin‐2 | |||||||||||||||
GAP‐43 |
|
||||||||||||||
NPTX1/2/R |
|
||||||||||||||
Nrg1 | |||||||||||||||
SNAP‐25 | |||||||||||||||
Synaptotagmin‐1 |
|
|
|
||||||||||||
VILIP‐1 | |||||||||||||||
Note: Blue inverted triangles () indicate a significant negative association, and green triangles (), respectively, indicate a significant positive association between CSF marker levels and neuropsychological performance. Black circles indicate no significant associations. Numeric value within shape corresponds to number of studies with this finding.
Abbreviations: AD, Alzheimers disease; Aβ‐, amyloid beta negative; Aβ+, amyloid beta positive; CBS, corticobasal syndrome; CU, cognitively unimpaired; CUf, cognitively unimpaired with familial history of AD; DLB, dementia with Lewy bodies; EAD, early‐onset Alzheimers disease; FTD, frontotemporal dementia; GAP‐43, growth‐associated protein 43; MCI, mild cognitive impairment; NfL, neurofilament‐light; Ng, neurogranin; NPTX1/R, neuronal pentraxin 1/receptor; Nrg1, neuregulin‐1; PSP, progressive supranuclear palsy; SNAP‐25, synaptosomal‐associated protein 25; VaD, vascular dementia; VILIP‐1, visinin‐like protein 1; α‐syn, alpha‐synuclein; β‐syn, beta‐synuclein.